VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012

Feb 7, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-02-06

Reporting Person: Emmens Matthew (Executive Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-02-06	Common Stock	S	2500	$36.39	Disposed	265101	Direct
2011-02-06	Common Stock	S	12900	$37.11	Disposed	252201	Direct
2011-02-06	Common Stock	S	40600	$38.08	Disposed	211601	Direct

Footnotes

F1: Transaction made pursuant to Mr. Emmens' company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $36.39 (range $35.64 to $36.61).

F3: Mr. Emmens undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $37.11 (range $36.68 to $37.67).

F5: Open market sales reported on this line occurred at a weighted average price of $38.08 (range $37.70 to $38.33).